Friday, April 3, 2026
30.4 C
Bengaluru

Indian Pharma Regional Performance Analysis & Summary

Overall Market Performance (IPM)
• The Indian Pharmaceutical Market (IPM) recorded a total value of ₹229,260.6 crore, with an overall growth of 7.6% for Dec’24.
• Out of 26 regions, 12 states/regions grew faster than the IPM growth rate of 7.6%, while the rest grew equal to or slower.

Regional Zone-Wise Performance
1. North Zone (₹62,928.3 Cr, 27% MS, 8.0% Growth)
• Top Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Delhi (₹10,756.3 Cr, 17% MS).
• Fastest Growing: Delhi (12.5%), Jammu & Kashmir (9.4%), Haryana (8.8%).
2. South Zone (₹60,758.9 Cr, 27% MS, 7.1% Growth)
• Top Contributors: Karnataka (₹13,486.8 Cr, 22% MS), Tamil Nadu (₹11,509.0 Cr, 19% MS).
• Fastest Growing: Chennai (11.6%), Telangana (8.9%), Tamil Nadu (8.2%).
3. East Zone (₹56,501.1 Cr, 25% MS, 7.4% Growth)
• Top Contributors: West Bengal (₹14,651.3 Cr, 26% MS), Bihar (₹12,078.9 Cr, 21% MS).
• Fastest Growing: Chhattisgarh (9.5%), Orissa (8.7%), Assam (7.6%).
4. West Zone (₹49,072.3 Cr, 21% MS, 8.0% Growth)
• Top Contributors: Maharashtra (₹19,780.5 Cr, 40% MS), Madhya Pradesh (₹10,154.7 Cr, 21% MS).
• Fastest Growing: Madhya Pradesh (9.8%), Maharashtra (8.6%), Gujarat (8.7%).

Key Highlights

✅ Fastest Growing State: Delhi (12.5%)
✅ Other High Growth Regions: Chennai (11.6%), Madhya Pradesh (9.8%)
✅ Largest Market Share Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Maharashtra (₹19,780.5 Cr, 40% MS), and West Bengal (₹14,651.3 Cr, 26% MS).
✅ North and West Zones had the highest growth rate (8.0%), while the South Zone had the slowest (7.1%).

Conclusion
• Delhi, Chennai, and Madhya Pradesh were the fastest-growing states.
• North and West zones led in growth, while the South zone expanded relatively slower.
• Key markets like Uttar Pradesh, Maharashtra, and West Bengal dominate market share.
• Overall, 12 states/regions outpaced the IPM growth rate of 7.6%, showing strong market potential.

Data Source: IQVIA

Hot this week

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Topics

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...
spot_img

Related Articles

spot_imgspot_img